In collaboration with neurologists and clinical research centres in North America and Europe, TauRx has started a new clinical trial, named LUCIDITY. A change in the design of this trial has recently been implemented, expanding the number of patients sought for the trial from 375 to 450 and permitting a broader range of patients, including those diagnosed with moderate Alzheimer’s disease, to become eligible for participation. The expanded trial uses well-accepted cognitive and functional assessment scales to confirm the potential benefits seen with its lead compound, LMTX®, in delaying the progression of Alzheimer’s disease, and includes an open-label phase during which all participants will receive LMTX®. Patients completing the full trial will also be eligible for continued use of LMTX® under an expanded access programme.
LUCIDITY has already restarted patient recruitment at some sites in the US and more are expected to open over the next 3 months. Recruitment at sites in Canada, the UK and certain European countries is expected to commence from March 2020. For further information, and to understand the eligibility criteria for the LUCIDITY trial, or to find a site closest to you, please use the following link:
Additional information on the study is also available via the following link:
TauRx’s tau aggregation inhibitors (TAIs) are the product of nearly 30 years of research, preclinical and clinical investigations.
The company’s second-generation TAI, LMTX®, has now completed three separate Phase 3 trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD). For more information on the Phase 3 trials, please click on the Phase 3 button below.